Adjuvant cisplatin‐based combined chemotherapy for lymph node ( LN )‐positive urothelial carcinoma of the bladder ( UCB ) after radical cystectomy ( RC ): a retrospective international study of >1500 patients
Authors:
- Morgan RouprêtMRMorgan Rouprêt
- Luis KluthLKLuis Kluth
- Michael RinkMRMichael Rink
- Derya TilkiDTDerya Tilki
- Harun FajkovicHFHarun Fajkovic
- Wassim KassoufWKWassim Kassouf
- Sebastian L. HofbauerSHSebastian L. Hofbauer
- Michela de MartinoMMMichela de Martino
- Pierre I. KarakiewiczPKPierre I. Karakiewicz
- Alberto BrigantiABAlberto Briganti
Open Access
- 6 June 2014
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 115 (5) , 722-727
Abstract
Objective: To compare outcomes of patients with lymph node ( LN )‐positive urothelial carcinoma of the bladder ( UCB ) treated with or without cisplatin‐based combined adjuvant chemotherapy ( AC ) after radical cystectomy ( RC ). Patients and Methods: We retrospectively analysed 1523 patients with LN ‐positive UCB , who underwent RC with bilateral pelvic LN dissection. All patients had no evidence of disease after RC . AC was administered within 3 months. Competing‐risks models were applied to compare UCB ‐related mortality. Results: Of the 1523 patients, 874 (57.4%) received AC . The cumulative 1‐, 2‐ and 5‐year UCB ‐related mortality rates for all patients were 16%, 36% and 56%, respectively. Administration of AC was associated with an 18% relative reduction in the risk of UCB ‐related death (subhazard ratio 0.82, P = 0.005). The absolute reduction in mortality was 3.5% at 5 years. The positive effect of AC was detectable in patients aged ≤70 years, in women, in pT3 –4 disease, and in those with a higher LN density and lymphovascular invasion. This study is limited by its retrospective and non‐randomised design, selection bias, the absence of central pathological review and lack in standardisation of LN dissection and cisplatin‐based protocols. Conclusion: AC seems to reduce UCB ‐related mortality in patients with LN ‐positive UCB after RC . Younger patients, women and those with high‐risk features such as pT3 –4 disease, a higher LN density and lymphovascular invasion appear to benefit most. Appropriately powered prospective randomised trials are necessary to confirm these findings.Keywords
This publication has 37 references indexed in Scilit:
- Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized TrialsEuropean Urology, 2014
- Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data BaseEuropean Urology, 2013
- ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant SettingsEuropean Urology, 2013
- Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomyBJU International, 2012
- Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trialAnnals of Oncology, 2011
- Maximizing Cure for Muscle-Invasive Bladder Cancer: Integration of Surgery and ChemotherapyEuropean Urology, 2011
- Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node–Positive Urothelial Bladder Cancer Following Radical CystectomyEuropean Urology, 2011
- Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancerCancer, 2010
- Complete long‐term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancerBJU International, 2005
- Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysisThe Lancet, 2003